Your browser doesn't support javascript.
loading
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini, Chiara; Antoniotti, Carlotta; Rossini, Daniele; Lonardi, Sara; Loupakis, Fotios; Pietrantonio, Filippo; Bordonaro, Roberto; Latiano, Tiziana Pia; Tamburini, Emiliano; Santini, Daniele; Passardi, Alessandro; Marmorino, Federica; Grande, Roberta; Aprile, Giuseppe; Zaniboni, Alberto; Murgioni, Sabina; Granetto, Cristina; Buonadonna, Angela; Moretto, Roberto; Corallo, Salvatore; Cordio, Stefano; Antonuzzo, Lorenzo; Tomasello, Gianluca; Masi, Gianluca; Ronzoni, Monica; Di Donato, Samantha; Carlomagno, Chiara; Clavarezza, Matteo; Ritorto, Giuliana; Mambrini, Andrea; Roselli, Mario; Cupini, Samanta; Mammoliti, Serafina; Fenocchio, Elisabetta; Corgna, Enrichetta; Zagonel, Vittorina; Fontanini, Gabriella; Ugolini, Clara; Boni, Luca; Falcone, Alfredo.
Afiliação
  • Cremolini C; Department of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Antoniotti C; Department of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Rossini D; Department of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Lonardi S; Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, IRCCS, Padua, Italy.
  • Loupakis F; Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, IRCCS, Padua, Italy.
  • Pietrantonio F; Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy; Oncology and Hemato-oncology Department, Università degli Studi di Milano, Milan, Italy.
  • Bordonaro R; Medical Oncology Unit, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione, Garibaldi Catania, Catania, Italy.
  • Latiano TP; Oncology Unit, Foundation IRCCS, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
  • Tamburini E; Oncology Unit, Ospedale degli Infermi, Rimini, Italy; Department of Oncology and Palliative Care, Cardinale G Panico, Tricase City Hospital, Tricase, Italy.
  • Santini D; Department of Medical Oncology, University Campus Biomedico, Rome, Italy.
  • Passardi A; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy.
  • Marmorino F; Department of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Grande R; Department of Medical Oncology, F Spaziani Hospital, Lazio, Italy.
  • Aprile G; Department of Oncology, University and General Hospital, Udine, Italy; Department of Oncology, San Bortolo General Hospital, Vicenza, Italy.
  • Zaniboni A; Medical Oncology Unit, Poliambulanza Foundation, Brescia, Italy.
  • Murgioni S; Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, IRCCS, Padua, Italy.
  • Granetto C; Department of Oncology, S Croce and Carle Teaching Hospital, Cuneo, Italy.
  • Buonadonna A; Department of Medical Oncology, IRCCS, Centro di Riferimento Oncologico National Cancer Institute, Aviano, Italy.
  • Moretto R; Department of Oncology, University Hospital of Pisa, Pisa, Italy.
  • Corallo S; Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
  • Cordio S; Medical Oncology Unit, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione, Garibaldi Catania, Catania, Italy.
  • Antonuzzo L; Medical Oncology Unit, Careggi University Hospital, Florence, Italy.
  • Tomasello G; Medical Oncology Unit, Azienda Socio-Sanitaria Territoriale of Cremona, Cremona Hospital, Cremona, Italy.
  • Masi G; Department of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Ronzoni M; Department of Oncology, Hospital San Raffaele, IRCCS, Milan, Italy.
  • Di Donato S; Department of Medical Oncology, General Hospital, Prato, Italy.
  • Carlomagno C; Department of Clinical Medicine and Surgery, University Federico II, Napoli, Italy.
  • Clavarezza M; Medical Oncology Unit, Ente Ospedaliero Ospedali Galliera, Genoa, Italy.
  • Ritorto G; Struttura Semplice Dipartimentale, ColoRectal Cancer Unit, Department of Oncology, Azienda Ospedaliero-Universitaria, Città della Salute e della Scienza di Torino, Turin, Italy.
  • Mambrini A; Oncological Department, Azienda UnitàSanitaria Locale, Toscana Nord Ovest, Oncological Unit of Massa Carrara, Carrara, Italy.
  • Roselli M; Department of Systems Medicine, Medical Oncology Unit, Tor Vergata University, Rome, Italy.
  • Cupini S; Department of Oncology, Division of Medical Oncology, Azienda Toscana Nord Ovest, Livorno, Italy.
  • Mammoliti S; Medical Oncology, IRCCS, Ospedale San Martino Istituto Scientifico Tumori, Genoa, Italy.
  • Fenocchio E; Department of Medical Oncology, Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia, IRCCS, Candiolo, Italy.
  • Corgna E; Unit of Medical Oncology, Ospedale Santa Maria della Misericordia, Perugia, Italy.
  • Zagonel V; Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, IRCCS, Padua, Italy.
  • Fontanini G; Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
  • Ugolini C; Department of Laboratory, Pathology section, University Hospital of Pisa, Pisa, Italy.
  • Boni L; Clinical Trials Coordinating Center, Toscano Cancer Institute, University Hospital Careggi, Florence, Italy.
  • Falcone A; Department of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy. Electronic address: alfredo.falcone@med.unipi.it.
Lancet Oncol ; 21(4): 497-507, 2020 04.
Article em En | MEDLINE | ID: mdl-32164906
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Camptotecina / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Bevacizumab / Antineoplásicos Imunológicos Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Camptotecina / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Bevacizumab / Antineoplásicos Imunológicos Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália